Driving enterprise value with RWD

Mr. Price is Executive VP, Chief Operating Officer and co-Founder of Promontory Therapeutics, and has been responsible for strategy and operations across the company's activities since inception. Mr. Price helped negotiate the original license for the company's PT-112 development program, and helps to oversee clinical and translational research and development, manufacturing and external relations. He was responsible for the company's clinical trials collaboration jointly with Pfizer and Merck KGaA, Darmstadt, Germany, leads its relationship under a formal CRADA with the National Cancer Institute (NCI), and serves as the U.S. regulatory agent with FDA. He previously held research and managerial roles in the NGO and non-profit sectors working in the US and Germany. He holds an AB from Princeton University, graduating summa cum laude and Phi Beta Kappa, and earned his MBA from Columbia Business School as a Chazen Society Fellow in International Business. His resulting focus was on mission-driven entrepreneurship, whereby he found his home in biotech and oncology drug development. He is a frequent contributor to industry panel discussions and podcasts, and is a member of ASCO and ESMO. 

Dr. Glover is currently Chief Executive Officer of MycRx Holdings Inc., a privately held drug discovery company and serves as a consultant to the biotech industry. He has been a director of Lite Strategy (formerly MEI Pharma) since June 2013. Previously, he served as President and Chief Executive Officer of Sierra Oncology (NASDAQ: SRRA), a drug development company focused on advancing targeted therapeutics for the treatment of patients with cancer, from July 2014 through May 2020. Prior to joining Sierra, he served as President and Chief Executive Officer of YM Biosciences, an oncology drug development company, from November 2010 until its acquisition by Gilead Sciences in February 2013. Previously, Dr. Glover was President and Chief Executive Officer of Viventia Biotech, a biopharmaceutical company involved in the discovery and development of monoclonal antibody-based technologies for the treatment of cancer, which he joined after serving as an investment manager for MDS Capital, a life sciences venture capital firm. Dr. Glover holds a B.Sc. (Hons) in Chemistry from the University of East Anglia, U.K., a M.Sc. in Chemistry from the University of British Columbia, Canada, and a Ph.D. in Chemistry from Simon Fraser University, Canada.

Brad is the Co-Founder of Highlander Health, and an oncologist, trialist, entrepreneur, and product leader dedicated to driving transformation at the intersection of research and care. He most recently led product at Verily, which he joined upon Verily’s acquisition of SignalPath, a clinical research technology company he founded and led as CEO. In addition to past roles at Flatiron Health, Texas Oncology, US Oncology, and Duke University, Brad gives his passion and leadership to a wide range of philanthropic organizations, including the National Outdoor Leadership School.

Andy Moye is currently the Senior Vice President and General Manager of Data Products at Tempus. He was previously CEO and board member for Paige, a spinout company from Memorial Sloan Kettering Cancer Center in New York City.  Andy began his career as a Flight Officer in the U.S. Navy, flying missions in Iraq and the Middle East. He has worked across the molecular diagnostics, biotechnology, real-world data, and life sciences industries at the forefront of precision medicine in oncology, notably serving as Head of Commercial Operations in North America and Latin America for Philips Digital Pathology solutions, and in senior executive roles at leading healthcare companies including Ontada, a division of McKesson, Caris Life Sciences, and WaferGen Bio-systems, now part of Takara Bio. He has a Bachelor of Science in Physiology from the University of Arizona, an MBA from the University of Florida, and a PhD in Health Economics from Walden University.